Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
EYPT
EYPT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
EYPT News
Wall Street Analysts Adjust Ratings
5d ago
Benzinga
EyePoint, Inc. Q4 2025 Earnings Call Insights
5d ago
seekingalpha
EyePoint Pharmaceuticals Q4 Earnings Miss Expectations
6d ago
seekingalpha
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4
Mar 03 2026
seekingalpha
iShares Expanded Tech-Software ETF Underperforms
Feb 23 2026
NASDAQ.COM
EYPT Options Trading Analysis and Strategies
Feb 03 2026
NASDAQ.COM
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
Dec 31 2025
Benzinga
EyePoint CEO Jay Duker to Present at 2026 J.P. Morgan Healthcare Conference
Dec 17 2025
Globenewswire
EyePoint Grants 137,000 Stock Options to New Employees as Inducement Awards
Dec 16 2025
Globenewswire
EyePoint Grants 137,000 Stock Options to New Employees as Inducement Awards
Dec 16 2025
Newsfilter
Market Update: Health Care Stocks Show Varied Performance Ahead of Wednesday's Opening Bell
Nov 19 2025
Yahoo Finance
EyePoint Receives Favorable Endorsement from Independent Data Safety Monitoring Committee for Key Phase 3 Trials of DURAVYU™ in Wet Age-Related Macular Degeneration
Nov 19 2025
Newsfilter
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Predictions Have Deteriorated Slightly Following Its Recent Report
Nov 09 2025
Yahoo Finance
RBC Capital Reaffirms Outperform Rating for EyePoint Pharmaceuticals and Increases Price Target to $39
Nov 06 2025
Benzinga
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Aug 06 2025
Newsfilter
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
Jul 29 2025
Newsfilter
Show More News
